Impairment of alternative macrophage activation delays cutaneous leishmaniasis in nonhealing BALB/c mice

Journal of Immunology

Volumn 176, Issue 2, 2006, Pages 1115-1121

  Hölscher, Christoph ^a,b   Arendse, Berenice ^a   Schwegmann, Anita ^a   Myburgh, Elmarie ^a   Brombacher, Frank ^a  

^a UNIVERSITY OF CAPE TOWN   (South Africa)

^b RESEARCH CENTER BORSTEL   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ARGINASE; GAMMA INTERFERON; IMMUNOGLOBULIN E; IMMUNOGLOBULIN G1; IMMUNOGLOBULIN G2A; IMMUNOGLOBULIN G2B; IMMUNOGLOBULIN G3; INTERLEUKIN 13 RECEPTOR; INTERLEUKIN 4 RECEPTOR; INTERLEUKIN 4 RECEPTOR ALPHA;

ANIMAL CELL; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; CYTOKINE RELEASE; DISEASE COURSE; ENZYME ACTIVITY; ENZYME LINKED IMMUNOSORBENT ASSAY; IMMUNE RESPONSE; INFECTION SENSITIVITY; LEISHMANIA MAJOR; MACROPHAGE; MACROPHAGE ACTIVATION; MOUSE; NEUTROPHIL; NONHUMAN; PRIORITY JOURNAL; SKIN LEISHMANIASIS; TH1 CELL; TH2 CELL;

EID: 30744477705     PISSN: 00221767     EISSN: None     Source Type: Journal    
DOI: 10.4049/jimmunol.176.2.1115     Document Type: Article

References (40)

1. Alexander, J., A. R. Satoskar, and D. G. Russell. 1999. Leishmania species: models of intracellular parasitism. J. Cell Sci. 112 (Pt. 18): 2993-3002.
2. Kopf, M., F. Brombacher, G. Köhler, G. Kienzle, K. H. Widmann, K. Lefrang, C. Humborg, B. Ledermann, and W. Solbach. 1996. IL-4-deficient BALB/c mice resist infection with Leishmania major. J. Exp. Med. 184: 1127-1136.
3. Matthews, D. J., C. L. Emson, G. J. McKenzie, H. E. Jolin, J. M. Blackwell, and A. N. McKenzie. 2000. IL-13 is a susceptibility factor for Leishmania major infection. J. Immunol 164: 1458-1462.
4. Mohrs, M., B. Ledermann, G. Köhler, A. Dorfmüller, A. Gessner, and F. Brombacher. 1999. Differences between IL-4- and IL-4 receptor α-deficient mice in chronic leishmaniasis reveal a protective role for IL-13 receptor signaling. J. Immunol. 162: 7302-7308.
5. Stamm, L. M., A. Raisanen-Sokolowski, M. Okano, M. E. Russell, J. R. David, and A. R. Satoskar. 1998. Mice with STAT6-targeted gene disruption develop a Th1 response and control cutaneous leishmaniasis. J. Immunol. 161: 6180-6188.
6. Brombacher, F. 2000. The role of interleukin-13 in infectious diseases and allergy. BioEssays 22: 646-656.
7. Mohrs, M., C. Hölscher, and F. Brombacher. 2000. Interleukin-4 receptor α-deficient BALB/c mice show an unimpaired T helper 2 polarization in response to Leishmania major infection. Infect. Immun. 68: 1773-1780.
8. Herbert, D. R., C. Hölscher, M. Mohrs, B. Arendse, A. Schwegmann, M. Radwanska, M. Leeto, R. Kirsch, P. Hall, H. Mossmann, et al. 2004. Alternative macrophage activation is essential for survival during schistosomiasis and downmodulates T helper 1 responses and immunopathology. Immunity 20: 623-635.
9. Gordon, S. 2003. Alternative activation of macrophages. Nat. Rev. Immunol. 3: 23-35.
10. Clausen, B. E., C. Burkhardt, W. Reith, R. Renkawitz, and I. Förster. 1999. Conditional gene targeting in macrophages and granulocytes using LysMcre mice. Transgenic Res. 8: 265-277.
11. Kropf, P., K. Brunson, and I. Müller. 2002. The leishmaniasis model. In Immunology of Infection, Vol. 25. S. H. E. Kaufmann and D. Kabelitz, eds. Academic Press, London, pp. 463-502.
12. Corraliza, I. M., M. L. Campo, G. Soler, and M. Modolell. 1994. Determination of arginase activity in macrophages: a micromethod. J. Immunol. Methods 174: 231-235.
13. Müller, I., M. Freudenberg, P. Kropf, A. F. Kiderlen, and C. Galanos. 1997. Leishmania major infection in C57BL/10 mice differing at the Lps locus: a new non-healing phenotype. Med. Microbiol. Immunol. 186: 75-81.
14. Diefenbach, A., H. Schindler, M. Röllinghoff, W. M. Yokoyama, and C. Bogdan. 1999. Requirement for type 2 NO synthase for IL-12 signaling in innate immunity. Science 284: 951-955.
15. Green, S. J., S. Mellouk, S. L. Hoffman, M. S. Meltzer, and C. A. Nacy. 1990. Cellular mechanisms of nonspecific immunity to intracellular infection: cytokine-induced synthesis of toxic nitrogen oxides from L-arginine by macrophages and hepatocytes. Immunol. Lett. 25: 15-19.
16. Liew, F. Y., S. Millott, C. Parkinson, R. M. Palmer, and S. Moncada. 1990. Macrophage killing of Leishmania parasite in vivo is mediated by nitric oxide from L-arginine. J. Immunol. 144: 4794-4797.
17. + T cells correlates with Th1/Th2 phenotype. J. Immunol. 160: 5347-5354.
18. Rutschman, R., R. Lang, M. Hesse, J. N. Ihle, T. A. Wynn, and P. J. Murray. 2001. Cutting edge: Stato-dependent substrate depletion regulates nitric oxide production. J. Immunol. 166: 2173-2177.
19. Reiner, S. L., and R. M. Locksley. 1995. The regulation of immunity to Leishmania major. Annu. Rev. Immunol. 13: 151-177.
20. Sadick, M. D., F. P. Heinzel, B. J. Holaday, R. T. Pu, R. S. Dawkins, and R. M. Locksley. 1990. Cure of murine leishmaniasis with anti-interleukin 4 monoclonal antibody: evidence for a T cell-dependent, interferon γ-independent mechanism. J. Exp. Med. 171: 115-127.
21. Noben-Trauth, N., P. Kropf, and I. Müller. 1996. Susceptibility to Leishmania major infection in interleukin-4-deficient mice. Science 271: 987-990.
22. Noben-Trauth, N., W. E. Paul, and D. L. Sacks. 1999. IL-4- and IL-4 receptor-deficient BALB/c mice reveal differences in susceptibility to Leishmania major parasite substrains. J. Immunol. 162: 6132-6140.
23. Alexander, J., F. Brombacher, H. A. McGachy, A. N. McKenzie, W. Walker, and K. C. Carter. 2002. An essential role for IL-13 in maintaining a non-healing response following Leishmania mexicana infection. Eur. J. Immunol. 32: 2923-2933.
24. Barner, M., M. Mohrs, F. Brombacher, and M. Kopf. 1998. Differences between IL-4R α-deficient and IL-4-deficient mice reveal a role for IL-13 in the regulation of Th2 responses. Curr. Biol. 8: 669-672.
25. Kopf, M., G. G. Le, M. Bachmann, M. C. Lamers, H. Bluethmann, and G. Köhler. 1993. Disruption of the murine IL-4 gene blocks Th2 cytokine responses. Nature 362: 245-248.
26. Belkaid, Y., K. F. Hoffmann, S. Mendez, S. Kamhawi, M. C. Udey, T. A. Wynn, and D. L. Sacks. 2001. The role of interleukin (IL)-10 in the persistence of Leishmania major in the skin after healing and the therapeutic potential of anti-IL-10 receptor antibody for sterile cure. J. Exp. Med. 194: 1497-1506.
27. Li, J., C. A. Hunter, and J. P. Farrell. 1999. Anti-TGF-β treatment promotes rapid healing of Leishmania major infection in mice by enhancing in vivo nitric oxide production. J. Immunol. 162: 974-979.
28. Biedermann, T., S. Zimmermann, H. Himmelrich, A. Gumy, O. Egeter, A. K. Sakrauski, I. Seegmüller, H. Voigt, P. Launois, A. D. Levine, et al. 2001. IL-4 instructs TH1 responses and resistance to Leishmania major in susceptible BALB/c mice. Nat. Immunol. 2: 1054-1060.
29. Byrs, L., A. Beschin, G. G. Raes, G. G. Hassanzadeh, W. Noel, J. Brandt, F. Brombacher, and P. de Baetselier. 2005. Reactive oxygen species and 12/15-lipoxygenase contribute to the anti-proliferative capacity of alternatively activated myeloid cells elicited during helminth infection. J. Immunol. 174: 6095-6104.
30. Stenger, S., N. Donhauser, H. Thuring, M. Röllinghoff, and C. Bogdan. 1996. Reactivation of latent leishmaniasis by inhibition of inducible nitric oxide synthase. J. Exp. Med. 183: 1501-1514.
31. Kropf, P., M. A. Freudenberg, M. Modolell, H. P. Price, S. Herath, S. Antoniazi, C. Galanos, D. F. Smith, and I. Müller. 2004. Toll-like receptor 4 contributes to efficient control of infection with the protozoan parasite Leishmania major. Infect. Immun. 72: 1920-1928.
32. Arendse, B., S. J. Van, and F. Brombacher. 2005. IL-9 is a susceptibility factor in Leishmania major infection by promoting detrimental Th2/type 2 responses. J. Immunol. 174: 2205-2211.
33. Kropf, P., J. M. Fuentes, E. Fahnrich, L. Arpa, S. Herath, V. Weber, G. Soler, A. Celada, M. Modolell, and I. Müller. 2005. Arginase and polyamine synthesis are key factors in the regulation of experimental leishmaniasis in vivo. FASEB J. 19: 1000-1002.
34. Bogdan, C., S. Stenger, M. Röllinghoff, and W. Solbach. 1991. Cytokine interactions in experimental cutaneous leishmaniasis. Interleukin 4 synergizes with interferon-γ to activate murine macrophages for killing of Leishmania major amastigotes. Eur. J. Immunol. 21: 327-333.
35. Stenger, S., W. Solbach, M. Röllinghoff, and C. Bogdan. 1991. Cytokine interactions in experimental cutaneous leishmaniasis. II. Endogenous tumor necrosis factor-α production by macrophages is induced by the synergistic action of interferon (IFN)-γ and interleukin (IL) 4 and accounts for the antiparasitic effect mediated by IFN-γ and IL 4. Eur. J. Immunol. 21: 1669-1675.
36. Bogdan, C., Y. Vodovotz, J. Paik, Q. W. Xie, and C. Nathan. 1994. Mechanism of suppression of nitric oxide synthase expression by interleukin-4 in primary mouse macrophages. J. Leukocyte Biol. 55: 227-233.
37. Munder, M., K. Eichmann, J. M. Moran, F. Centeno, G. Soler, and M. Modolell. 1999. Th1/Th2-regulated expression of arginase isoforms in murine macrophages and dendritic cells. J. Immunol. 163: 3771-3777.
38. Lima, G. M., A. L. Vallochi, U. R. Silva, E. M. Bevilacqua, M. M. Kiffer, and I. A. Abrahamsohn. 1998. The role of polymorphonuclear leukocytes in the resistance to cutaneous leishmaniasis. Immunol. Lett. 64: 145-151.
39. + Th2 response in BALB/c mice infected with Leishmania major. J. Immunol. 165: 2628-2636.
40. Roberts, S. C., M. J. Tancer, M. R. Polinsky, K. M. Gibson, O. Heby, and B. Ullman. 2004. Arginase plays a pivotal role in polyamine precursor metabolism in Leishmania: characterization of gene deletion mutants. J. Biol. Chem. 279: 23668-23678.